GlobalData on MSN3d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...
BMJ2d
Gilead’s anti-diversion clause for lenacapavir exploits vulnerable communities
Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
World AIDS Day: Twice-Yearly HIV Shot Sparks Hope, Raises Questions On Global Reach
In a report issued to mark World AIDS Day on Sunday, UNAIDS said that the number of AIDS deaths last year—an estimated ...
Five things you should know about the HIV epidemic
Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...
Morningstar3d
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
The use of lenacapavir for the prevention of HIV is investigational and has not been determined to be safe or efficacious and is not approved anywhere globally. About Gilead HIV For more than 35 ...
'Huge relief' as new drug found to effectively prevent HIV infection
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...
The New England Journal of Medicine4d
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in ...
Investing3d
Gilead reports high efficacy in HIV prevention trial
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) released pivotal Phase 3 trial results for its investigational HIV prevention drug, lenacapavir, which demonstrated a 96% reduction in HIV ...